Johnson & Johnson (NYSE:JNJ) Unveils Promising CAR T-Cell Therapy for B-Cell Lymphoma
Johnson & Johnson (NYSE:JNJ) recently announced promising Phase 1b study results for its CAR T-cell therapy, JNJ-90014496, indicating potential efficacy in treating large B-cell lymphoma. During the same period, the company saw a 7% share price increase. While the broader market remained flat over the last 7 days, Johnson & Johnson's advancements in cancer treatment likely added weight to its positive stock movement. Other positive developments, such as promising results in acute myeloid...